【レポートの概要(一部)】
1. Report Overview
1.1 Overview of the World Market for Those Medicines
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by This Analysis
1.5 Who is This Study For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQ)
1.8 Some Associated Reports
1.9 About Visiongain
2. Introduction to Anti-Cancer Kinase Inhibitors
2.1 What are Protein Kinases?
2.2 Protein Kinases in Oncology
2.3 Mechanisms for Kinase Inhibition
2.4 Glossary of Terms
3. Anti-Cancer Kinase Inhibitors: World Market 2014-2024
3.1 The Global Market for Anti-Cancer Kinase Inhibitors in 2013
3.1.1 Leading Anti-Cancer Kinase Inhibitors by Sales, 2013
3.1.2 Leading Companies in the Protein Kinase Inhibitor Market
3.2 World Protein Kinase Inhibitors for Oncology Market: Sales Forecast by Class, 2014-2024
3.2.1 Changing Market Shares by Segment 2014-2024
3.2.2 Leading Anti-Cancer Kinase Inhibitors Manufacturers, 2014-2024
3.3 Bcr-Abl Inhibitors Lead the Protein Kinase Inhibitors for Oncology Market in 2013
3.3.1 Bcr-Abl Kinase Inhibitors: Drivers and Restraints 2014-2024
3.4 Imbruvica and Other Novel Kinase Inhibitors Will Eventually Dominate the Market
3.4.1 Other Kinase Inhibitors: Drivers and Restraints, 2014-2024
4. Leading National and Regional Markets, 2014-2024
4.1 Regional Breakdown of the World Protein Kinase Inhibitors for Drugs Treating Cancer
4.2 World Protein Kinase Inhibitors for Oncology Market: Regional Forecast 2014-2024
4.2.1 How Will Regional Market Shares Change Through to 2024?
4.3 The US Anti-Cancer Kinase Inhibitor Market Forecast, 2014-2024
4.4 The US Market: Drivers and Restraints, 2014-2024
4.5 The EU Union Anti-Cancer Kinase Inhibitors Market Forecast, 2014-2024
4.5.1 EU Market: Drivers and Restraints
4.5.2 German Market Forecast, 2014-2024
4.5.3 French Market Forecast, 2014-2024
4.5.4 Italian Market Forecast, 2014-2024
4.5.5 UK Market Forecast, 2014-2024
4.5.6 Spanish Market Forecast, 2014-2024
4.6 The Japanese Anti-Cancer Kinase Inhibitor Market Forecast, 2014-2024
4.7 Forecasting Anti-Cancer Kinase Inhibitor Markets in Developing Countries, 2014-2024
4.7.1 Chinese Market Forecast, 2014-2024
4.7.2 Brazilian Market Forecast, 2014-2024
4.7.3 Russian Market Forecast, 2014-2024
4.7.4 Indian Market Forecast, 2014-2024
5. Leading Anti-Cancer Kinase Inhibitors Products, 2014-2024
5.1 Brc-Abl Inhibitors – Managed Care for Chronic Myeloid Leukaemia
5.1.1 Gleevec (imatinib) – Novartis
5.1.1.1 Historic Sales Performance
5.1.1.2 Lifecycle Management, Generic Challenges and Tasigna
5.1.1.3 Gleevec Forecast, 2014-2024
5.1.2 Sprycel (dasatanib) – Bristol-Myers Squibb
5.1.2.1 Patents and Market Exclusivity
5.1.2.2 Historic Sales Performance
5.1.2.3 Sprycel Forecast, 2014-2024
5.1.3 Tasigna (nilotinib) – Novartis
5.1.3.1 Indications and Market Exclusivity
5.1.3.2 Historic Sales Performance
5.1.3.3 Tasigna Forecast, 2014-2024
5.1.4 Bosulif (bosutinib) – Pfizer
5.1.4.1 Bosulif Forecast, 2014-2024
5.1.5 Iclusig (ponatinib) – ARIAD Pharmaceuticals
5.1.5.1 Iclusig Forecast, 2014-2024
5.2 EGFR Inhibitors
5.2.1 Tarceva (erlotinib) – Roche/Astellas
5.2.1.1 Patent Litigation and Market Exclusivity
5.2.1.2 Historic Sales Performance, 2004-2012
5.2.1.3 Tarceva Forecast, 2014-2024
5.2.2 Iressa (gefitinib) – AstraZeneca
5.2.2.1 Historic Sales Performance, 2003-2012
5.2.2.2 Iressa Forecast, 2014-2024
5.2.3 Gilotrif (afatinib) – Boehringer Ingelheim
5.2.3.1 Gilotrif Forecast, 2014-2024
5.3 Angiogenesis Inhibitors
5.3.1 Nexavar (sorafenib) – Bayer/Onyx
5.3.1.1 Historic Sales Performance, 2006-2012
5.3.1.2 Nexavar Forecast, 2014-2024
5.3.2 Sutent (sunitinib) – Pfizer
5.3.2.1 Historic Sales Performance, 2006-2012
5.3.2.2 Sutent Forecast, 2014-2024
5.3.3 Votrient (pazopanib) – GSK
5.3.3.1 Historic Sales Performance, 2010-2012
5.3.3.2 Votrient Forecast, 2014-2024
5.3.4 Inlyta (axitinib) – Pfizer
5.3.4.1 Inlyta Forecast, 2014-2024
5.4 BRAF and MEK Inhibitors
5.4.1 Zelboraf (vemurafenib) – Roche/Daiichi Sankyo
5.4.1.1 Zelboraf Forecast, 2014-2024
5.4.2 Mekinist (trametinib) and Tafinlar (dabrafenib) – GSK
5.4.2.1 Mekinist Forecast, 2014-2024
5.4.2.2 Tafinlar Forecast, 2014-2024
5.5 mTOR Inhibitors
5.5.1 Afinitor (everolimus) – Novartis
5.5.1.1 Patents and Market Exclusivity
5.5.1.2 Historic Sales Performance
5.5.1.3 Afinitor Forecast, 2014-2024
5.5.2 Torisel (temsirolimus) – Pfizer
5.5.2.1 Torisel Forecast, 2014-2024
5.6 Other leading Anticancer Kinase Inhibitors
5.6.1 Imbruvica (ibrutinib) –J&J/Pharmacyclics
5.6.1.1 Imbruvica Forecast, 2014-2024
5.6.2 Jakafi (ruxolitinib) – Novartis/Incyte
5.6.2.1 Jakafi Forecast, 2014-2024
5.6.3 Xalkori (crizotinib) – Pfizer
5.6.3.1 Xalkori Forecast, 2014-2024
5.6.4 Cometriq (cabozantinib) – Exelixis
5.6.4.1 Cometriq Forecast, 2014-2024
5.6.5 Caprelsa (vandetanib) – AstraZeneca
5.6.5.1 Caprelsa Forecast, 2014-2024
5.6.6 Tykerb (lapatinib) – GSK
5.6.6.1 Historic Sales Performance, 2007-2012
5.6.6.2 Tykerb Forecast, 2014-2024
5.6.7 Stivarga (regorafenib) – Bayer
5.6.7.1 Stivarga Forecast, 2014-2024
6. Anti-Cancer Kinase Inhibitors: R&D Pipeline, 2014-2024
6.1 Cyclin-Dependent Kinase 4/6 Inhibitors in Development
6.1.1 Palbociclib – Pfizer
6.1.1.1 Palbociclib Forecast, 2014-2024
6.1.2 LEE-011 – Novartis
6.1.2.1 LEE-011 Forecast, 2014-2024
6.1.3 Bemaciclib (LY2835219) – Eli Lilly
6.1.3.1 Bemaciclib Forecast, 2014-2024
6.2 Anaplastic Lymphoma Kinase (ALK) Inhibitors In Development
6.2.1 Alectinib – Roche
6.2.1.1 Alectinib Forecast, 2014-2024
6.2.2 Ceritinib (LDK378) – Novartis
6.2.2.1 Ceritinib Forecast, 2014-2024
6.2.3 AP26113 – ARIAD
6.3 Bruton’s Tyrosine Kinase and PI3K Inhibitors in Development
6.3.1 Idelalisib – Gilead
6.3.1.1 Idelalisib Forecast, 2014-2024
6.3.2 RG7601 (ABT-199) – Roche/AbbVie
6.3.2.1 ABT-199 Sales Forecast, 2014-2024
6.3.3 IPI-145 – Infinity Pharmaceuticals
6.3.3.1 IPI-145 Forecast, 2014-2024
6.3.4 Buparlisib (BKM120) – Novartis
6.3.4.1 Buparlisib Forecast, 2014-2024
6.3.5 ONO-4059 – Ono Pharmaceuticals
6.3.6 Copanlisib (BAY 80-6946) – Bayer
6.3.7 Pictilisib (GDC-0941) – Roche
6.3.8 BEZ235 – Novartis
6.4 MEK and BRAF Inhibitors in Development
6.4.1 Cobimetinib (GDC-0973) – Roche
6.4.1.1 Cobimetinib Forecast, 2014-2024
6.4.2 Encorafenib (LGX818) – Novartis
6.4.3 Binimetinib (MEK162) – Novartis
6.4.4 Selumetinib (AZD 6244) – AstraZeneca
6.5 Other Kinase Inhibitors in Development
6.5.1 Volasertib – Boehringer Ingelheim
6.5.1.1 Volasertib Forecast, 2014-2024
6.5.2 Neratinib (PB272) – Puma Biotechnology
6.5.3 Tivantinib (ARQ197) – Daiichi Sankyo
6.5.4 Dovotinib (TKI258) – Novartis
6.5.5 Dacomitinib – Pfizer
6.5.6 CO-1686 – Clovis Oncology
7. Qualitative Analysis of the Anti-Cancer Kinase Inhibitor Market, 2014-2024
7.1 SWOT Analysis of the Protein Kinase Inhibitors for Oncology Market
7.2 Strengths
7.2.1 Oral Dosage Preferred Over Injection
7.2.2 Stratifying Patients Offers Clinical and Commercial Benefits
7.2.3 Targeted Kinase Inhibitor are Generally Well Tolerated
7.2.4 A Strong Pipeline of Novel Inhibitors Will Drive Market Growth
7.3 Weaknesses
7.3.1 Small Molecule Kinase Inhibitors Will Experience Generic Competition
7.3.2 Competitor Biologics Offer Differentiated Mechanisms of Action
7.3.3 Monoclonal Antibodies are More Specific than Small Molecules
7.4 Opportunities
7.4.1 Novel Targets Identified Through Cancer Genomics
7.4.2 Combination Therapies Bring Additive Benefits
7.4.3 Commercial Success Leveraged by Clinical Benefit
7.5 Threats
7.5.1 Small Molecules Generics Are Easy to Produce
7.5.2 Individual Kinase Targets are Rapidly Becoming Crowded
7.6 STEP Analysis of the Protein Kinase Inhibitors for Oncology Market
7.7 Porter’s Five Forces Analysis of the Anti-Cancer Kinase Inhibitor Market, 2014-2024
7.7.1 Rivalry Among Competitors
7.7.2 Threat of New Entrants
7.7.3 Power of Suppliers
7.7.4 Power of Buyers
7.7.5 Threat of Substitutes
8. Research Interview
8.1 Interview with Dr Lawrence Bloch, Chief Finance and Business Officer, Infinity Pharmaceuticals, United States
8.1.1 Positioning a Novel Therapeutic in Blood Cancer Indications
8.1.2 Combining Therapies Offers Significant Benefit to Patients
8.1.3 Potential in Rheumatoid Arthritis and Blood Cancers
9. Conclusions
9.1 The Global Anti-Cancer Kinase Inhibitors Market to 2024
9.1.1 A Robust Pipeline of Innovative Drugs Driving Market Growth
9.2 Leading National Markets for Anti-Cancer Kinase Inhibitors to 2024
【レポート販売概要】
■ タイトル:世界の癌治療用キナーゼ阻害剤市場:Brc-Abl阻害剤/EGFR阻害剤/血管新生阻害剤/BRAF・MEK阻害剤/mTOR阻害剤など■ 英文:Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts 2014-2024
■ 発行日:2014年6月
■ 調査会社:visiongain
■ 商品コード:VISG409052
■ 調査対象地域:グローバル
- オキシラン(エチレンオキシド)の国際貿易動向This report examines international trade and worldwide market trends pertaining to oxirane (ethylene oxide). The report will be of considerable interest primarily to relevant strategic planners, senior company officials and importers/exporters, since it features invaluable information on oxirane (ethylene oxide) export/import operations segmented by country and region. The report covers the 2007-2 …
- 世界のNAND型フラッシュメモリ市場動向(2014-2018)About NAND Flash Memory NAND flash memory is a non-volatile storage technology that enables rapid read and write operations in memory cards. With respect to the design of NAND flash memory chips, the memory cells in these chips are connected in a series that resembles a NAND gate. The series connection consumes less space than a parallel connection, reducing the cost of NAND flash devices. This ma …
- 生体接着剤の世界市場予測(~2024年)The global bioadhesives market size is projected to register a CAGR of 10.0%, in terms of value, between 2019 and 2024. The global bioadhesives market size is projected to grow from USD 5.6 billion in 2019 to USD 9.1 billion by 2024, at a CAGR of 10.0%, between 2019 and 2024. The demand for bioadhesives, especially for green products, is increasing due to their use across varied applications in va …
- 自動車用電動パワーステアリング(EPS)装置の世界市場動向・予測The EPS system market is projected to grow from 2016 to 2021, registering a CAGR of 7.29% during the forecast period. The EPS system eliminates the need for hydraulic pumps and belt-drive units, which were initially used in hydraulically assisted power steering systems. The report covers automotive EPS Market By Type (C-EPS, P-EPS, R-EPS), By Components (Electric Motors, Speed Sensor, Torque Senso …
- Privileged Identity Management(特権ユーザーID管理)ソリューションの世界市場About Privileged Identity Management Privileged identity management is a secure password management solution that manages administrator activity in critical environments such as applications and databases and network equipment such as routers, switches, and security appliances. Privileged identity management solutions are widely used by end-users to secure, audit, manage, and monitor all activitie …
- セルフサービス式キヨスクの世界市場2016-2020About Self-Service Kiosk A self-service, or interactive, kiosk is a customized computer terminal that is either standalone or networked and is used to access information and services conveniently. A self-service kiosk consists of a monitor, usually touch enabled, through which people can seek information of their choosing. Self-service kiosks enable service providers to cater to high customer traf …
- 流量計校正の世界市場2018-2022About Flowmeters A flowmeter measures the rate at which a fluid or gas passes through it. Calibration process in a flowmeter assures that measurements match the specified and reference values. Technavio’s analysts forecast the Global Flowmeter Calibration Market to grow at a CAGR of 6.19% during the period 2018-2022. Covered in this report The report covers the present scenario and the growth pros …
- 世界の4WD(四輪駆動)及びADW(全輪駆動)小型車市場(2008-2028)This latest just-auto report edition offers a global review of the OE 4WD and AWD sector, its suppliers, top markets, technologies and market forecasts. This global market study offers: Automotive OE 4WD and AWD market size estimates Latest technologies and trends Market share data tables Exclusive interviews with major companies Profiles of the major players including their strategies and prospec …
- 世界の警察近代化及びテロ対策市場(2014-2024)Summary The Global Police Modernization and Counter Terrorism Market 2014-2024 Report published by Strategic Defence Intelligence, provides readers with a detailed analysis of both historic and forecast global industry values, factors influencing demand, the challenges faced by industry participants, analysis of industry leading companies, and key news. Key Findings • The global Police Modernizati …
- 医療用シミュレーションの世界市場:製品・サービス別(モデルベースシミュレーション、Webベースシミュレーション、シミュレーショントレーニングサービス)、フィデリティ別(低フィデリティ、中フィデリティ、高フィデリティ)、エンドユーザー別(学術機関・研究センター、病院・診療所、軍事組織)Medical simulation is the virtual duplication of in situ activities or phenomenon, representing the functions and properties of a selective real abstract or process. It is used to train healthcare professionals using advanced healthcare technologies. The global medical simulation market was valued at $1,132 million in 2017 and is estimated to reach $ 3,251 million by 2025, registering a CAGR of 14 …
- 車両緊急通報システム(eCall)の世界市場2016-2020:標準取り付け、TPS取り付けAbout Automotive eCall eCall is an initiative by the transportation safety regulatory bodies to provide immediate assistance to people involved in accidents. It is a sub-system of telematics systems being installed in a vehicle. Implementation of eCall requires significant investment in infrastructure. In the case of a crash, it contacts the closest emergency center and forwards the GPS location o …
- 油圧シリンダーの世界市場2016-2020:農業、建設業、鉱業、資材運搬機器産業、産業機器産業、航空宇宙・防衛産業About Hydraulic Cylinder The hydraulic cylinder industry will see a steady growth during the forecast period due to a continuous demand from the agriculture, construction equipment, mining equipment, material handling equipment, industrial equipment, aerospace, and defense sectors. Technavio’s analysts forecast the global hydraulic cylinder market to grow at a CAGR of 4.39% during the period 2016- …
- 世界の小型自動車用OEバッテリー市場【2015年1月更新版】This latest just-auto report edition offers a global review of the OE batteries sector, its suppliers, top markets, technologies and market forecasts. This global market study offers: Automotive OE batteries market size estimates Latest technologies and trends Market share data tables Exclusive interviews with major companies Profiles of the major players including their strategies and prospects M …
- 4G機器の世界市場:コンポーネント別、技術別Wireless mobile communications are generally defined by generation designations. 4G is a fourth-generation of mobile network technology that enables faster internet than earlier generations such as 2G and 3G networks. The 4G equipment are categorized into Long-term Equipment (LTE) and Wi-max equipment. These equipment enable to increase network capacity and faster data transmission rates in areas …
- 世界のミサイル及びミサイル防衛システムの市場動向2013-2023:地域別分析"The Global Missiles and Missile Defense Systems Market 2013-2023 - Country Analysis: Market Profile" provides details of the key markets in each region, offering an analysis of the top segments of Missiles and Missile Defense Systems, expected to be in demand. It also investigates the top three expected Missiles and Missile Defense Systems programs, in terms of demand in the key markets in each r …